Skip to main content
. 2021 Jul 12;9(7):e002444. doi: 10.1136/jitc-2021-002444

Figure 5.

Figure 5

In vivo studies with affinity-attenuated HER-2/CD3 IgG BsAbs. (A.) In vivo redirected lysis activity of affinity-attenuated HER-2/CD3 IgG BsAbs (one dose, 5 mg/kg). Tumor growth was measured using the bioluminescence of the SKOV3-Luc cell line (top panel) or physically using caliper measurements (bottom panel). IgG BsAb treatment was performed only once, 1 day after tumor cell inoculation (black arrow). (B). SKOV3 In vivo dose response study (top panel) and anti-PD-1 antagonist or anti-4-1BB agonist combination study (bottom panel) with the CD3 affinity-attenuated HER-2/CD3 IgG BsAb (SP34_V100cT, IC50=280 nM). For the PD-1/4-1BB combination study, the HER-2/CD3 IgG BsAb was injected intraperitoneally on Day 3a (0.6 mg/kg) after tumor cell inoculation to reduce its observed efficacy. The PD-1 antagonist mAb and 4-1BB agonist mAb were injected on Day 7b (10 mg/kg) after tumor cell inoculation to allow a period for receptor upregulation on T cells. BsAb, bispecific antibody; mAb, monoclonal antibody; PD-1, Programmed cell death 1 aka CD279.